Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Oct 30;2019(10):CD002312.
doi: 10.1002/14651858.CD002312.pub4.

Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema

Emile S Altmann  1 , Iain Crossingham  2 , Stephen Wilson  2 , Huw R Davies  3
Affiliations
Meta-Analysis

Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema

Emile S Altmann et al. Cochrane Database Syst Rev. .

Abstract

Background: Pleural infection, including parapneumonic effusions and thoracic empyema, may complicate lower respiratory tract infections. Standard treatment of these collections in adults involves antibiotic therapy, effective drainage of infected fluid and surgical intervention if conservative management fails. Intrapleural fibrinolytic agents such as streptokinase and alteplase have been hypothesised to improve fluid drainage in complicated parapneumonic effusions and empyema and therefore improve treatment outcomes and prevent the need for thoracic surgical intervention. Intrapleural fibrinolytic agents have been used in combination with DNase, but this is beyond the scope of this review.

Objectives: To assess the benefits and harms of adding intrapleural fibrinolytic therapy to standard conservative therapy (intercostal catheter drainage and antibiotic therapy) in the treatment of complicated parapneumonic effusions and empyema.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and Embase, ClinicalTrials.gov and the World Health Organization (WHO) trials portal. We contacted trial authors for further information and requested details regarding the possibility of unpublished trials. The most recent search was conducted on 28 August 2019.

Selection criteria: Parallel-group randomised controlled trials (RCTs) in adult patients with post-pneumonic empyema or complicated parapneumonic effusions (excluding tuberculous effusions) who had not had prior surgical intervention or trauma comparing an intrapleural fibrinolytic agent (streptokinase, alteplase or urokinase) versus placebo or a comparison of two fibrinolytic agents.

Data collection and analysis: Two review authors independently extracted data. We contacted study authors for further information. We used odds ratios (OR) for dichotomous data and reported 95% confidence intervals (CIs). We used Cochrane's standard methodological procedures of meta-analysis. We applied the GRADE approach to summarise results and to assess the overall certainty of evidence.

Main results: We included in this review a total of 12 RCTs. Ten studies assessed fibrinolytic agents versus placebo (993 participants); one study compared streptokinase with urokinase (50 participants); and one compared alteplase versus urokinase (99 participants). The primary outcomes were death, requirement for surgical intervention, overall treatment failure and serious adverse effects. All studies were in the inpatient setting. Outcomes were measured at varying time points from hospital discharge to three months. Seven trials were at low or unclear risk of bias and two at high risk of bias due to inadequate randomisation and inappropriate study design respectively. We found no evidence of difference in overall mortality with fibrinolytic versus placebo (OR 1.16, 95% CI 0.71 to 1.91; 8 studies, 867 participants; I² = 0%; moderate certainty of evidence). We found evidence of a reduction in surgical intervention with fibrinolysis in the same studies (OR 0.37, 95% CI 0.21 to 0.68; 8 studies, 897 participants; I² = 51%; low certainty of evidence); and overall treatment failure (OR 0.16, 95% CI 0.05 to 0.58; 7 studies, 769 participants; I² = 88%; very low certainty of evidence, with evidence of significant heterogeneity). We found no clear evidence of an increase in adverse effects with intrapleural fibrinolysis, although this cannot be excluded (OR 1.28, 95% CI 0.36 to 4.57; low certainty of evidence). In a sensitivity analysis, the reduction in referrals for surgery and overall treatment failure with fibrinolysis disappeared when the analysis was confined to studies at low or unclear risk of bias. In a moderate-risk population (baseline 14% risk of death, 20% risk of surgery, 27% risk of treatment failure), intra-pleural fibrinolysis leads to 19 more deaths (36 fewer to 59 more), 115 fewer surgical interventions (150 fewer to 55 fewer) and 214 fewer overall treatment failures (252 fewer to 93 fewer) per 1000 people. A single study of streptokinase versus urokinase found no clear difference between the treatments for requirement for surgery (OR 1.00, 95% CI 0.13 to 7.72; 50 participants; low-certainty evidence). A single study of alteplase versus urokinase showed no clear difference in requirement for surgery (OR alteplase versus urokinase 0.46, 95% CI 0.04 to 5.24) but an increased rate of adverse effects, primarily bleeding, with alteplase (OR 5.61, 95% CI 1.16 to 27.11; 99 participants; low-certainty evidence). This translated into 154 (6 to 499 more) serious adverse events with alteplase compared with urokinase per 1000 people treated.

Authors' conclusions: In patients with complicated infective pleural effusion or empyema, intrapleural fibrinolytic therapy was associated with a reduction in the requirement for surgical intervention and overall treatment failure but with no evidence of change in mortality. Discordance between the negative largest trial of this therapy and other studies is of concern, however, as is an absence of significant effect when analysing low risk of bias trials only. The reasons for this difference are uncertain but may include publication bias. Intrapleural fibrinolytics may increase the rate of serious adverse events, but the evidence is insufficient to confirm or exclude this possibility.

PubMed Disclaimer

Conflict of interest statement

ESA: none known.

IC: received travel and training expenses from Hamilton Medical that are not connected to the topic of this review.

SW: none known.

HRD: is a member of Astra Zeneca COPD Advisory Board Interaction and has given lectures for and on behalf of Astra Zeneca, GSK and Boehringer‐Ingelheim in areas of COPD, ILD and asthma. No direct conflict of interest with work on fibrinolytic agents.

Figures

1
1
Funnel plot of comparison: 1 Fibrinolytic therapy versus placebo, outcome: 1.2 Referral for thoracic surgery (open or thorascopic).
2
2
Funnel plot of comparison: 1 Fibrinolytic therapy versus placebo, outcome: 1.3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
4
4
Study flow diagram for 2019 update.
5
5
Forest plot of comparison: 1 Fibrinolytic versus placebo (loculation and empyema), outcome: 1.1 Treatment failure‐ death.
6
6
Forest plot of comparison: 1 Fibrinolytic versus placebo (loculation and empyema), outcome: 1.2 Treatment failure‐ surgical intervention.
7
7
Forest plot of comparison: 1 Fibrinolytic therapy versus placebo, outcome: 1.3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy.
8
8
Forest plot of comparison: 1 Fibrinolytic versus placebo (loculation and empyema), outcome: 1.4 Significant treatment complications.
1.1
1.1. Analysis
Comparison 1 Fibrinolytic therapy versus placebo, Outcome 1 Mortality.
1.2
1.2. Analysis
Comparison 1 Fibrinolytic therapy versus placebo, Outcome 2 Referral for thoracic surgery (open or thorascopic).
1.3
1.3. Analysis
Comparison 1 Fibrinolytic therapy versus placebo, Outcome 3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy.
1.4
1.4. Analysis
Comparison 1 Fibrinolytic therapy versus placebo, Outcome 4 Serious adverse events.
2.1
2.1. Analysis
Comparison 2 Streptokinase versus urokinase, Outcome 1 Mortality.
2.2
2.2. Analysis
Comparison 2 Streptokinase versus urokinase, Outcome 2 Referral for thoracic surgery (open or thorascopic).
2.3
2.3. Analysis
Comparison 2 Streptokinase versus urokinase, Outcome 3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy.
2.4
2.4. Analysis
Comparison 2 Streptokinase versus urokinase, Outcome 4 Serious adverse events.
3.1
3.1. Analysis
Comparison 3 Alteplase versus urokinase, Outcome 1 Mortality.
3.2
3.2. Analysis
Comparison 3 Alteplase versus urokinase, Outcome 2 Referral for thoracic surgery (open or thorascopic).
3.3
3.3. Analysis
Comparison 3 Alteplase versus urokinase, Outcome 3 Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy.
3.4
3.4. Analysis
Comparison 3 Alteplase versus urokinase, Outcome 4 Serious adverse events.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Aleman 2015 {published data only}
    1. Aleman C, Porcel JM, Alegre J, Ruiz E, Bielsa S, Andreu J, et al. Intrapleural fibrinolysis with urokinase versus alteplase in complicated parapneumonic pleural effusions and empyemas: a prospective randomized study. Lung 2015;193(6):993‐1000. - PubMed
Bouros 1997 {published data only}
    1. Bouros D, Schiza S, Patsourakis G, Chalkiadakis G, Panagou P, Siafakas N. Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine 1997;155(1):291‐5. - PubMed
Bouros 1999 {published data only}
    1. Bouros D, Schiza S, Tzanakis N, Chalkiadakis G, Drositis J, Siafakas N. Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. American Journal for Respiratory and Critical Care Medicine 1999;159(1):37‐42. - PubMed
    1. Bouros D, Schiza SE, Drositis J, Tzanakis N, Papalexatos S, Mitrouska I, et al. Control study of intrapleural instillation of urokinase in the treatment of multi‐loculated pleural effusion and empyema. American Journal of Respiratory and Critical Care Medicine 1998;157(3 Suppl):A65.
    1. Schiza S, Bouros D, Maltezakis G, Drositis J, Tzanakis N, Siafakas NM. Intrapleural urokinase vs normal saline in the treatment of thoracic empyema: a randomized double blind study. European Respiratory Journal 1997;10(Suppl 25):455s.
Davies 1997 {published and unpublished data}
    1. Davies RJ, Traill ZC, Gleeson FV. Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax 1997;52(5):416‐21. - PMC - PubMed
Diacon 2004 {published data only}
    1. Diacon AH, Theron J, Schuurmans MM, Wal BW, Bolliger CT. Intrapleural streptokinase for empyema and complicated parapneumonic effusions. American Journal of Respiratory and Critical Care Medicine 2004;170(1):49‐53. - PubMed
Lin 2011 {published data only}
    1. Lin J‐C, Zhang C‐R, Li M, Zhou H, Niu Y‐Y, Liu X‐Y. Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated pleural effusions. Chinese Journal of Clinicians 2011;5(9):2610‐14.
    1. Lin J‐C, Zhang C‐R, Xu W‐M, Li M, Cui W‐L. Effectiveness and safety of intrapleural tissue plasminogen activator in the prevention of pleural thickening and loculated effusions by infective pleurisy. International Journal of Infectious Diseases 2011;15(suppl 1):S104‐5.
Maskell 2005 {published data only}
    1. Maskell NA, Davies CW, Nunn AJ, Hedley EL, Gleeson FV, Miller R, et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. New England Journal of Medicine 2005;352(9):865‐74. - PubMed
Misthos 2005 {published data only}
    1. Misthos P, Sepsas E, Konstantinou M, Athanassiadi K, Skottis I, Lioulias A. Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. European Journal of Cardio‐thoracic Surgery 2005;28(4):599‐603. - PubMed
Prasad 2009 {published data only}
    1. Prasad BNBM, Bhattacharyya D, Luthra M, Mathur AD. Management of empyema thoracis with pleural pigtail drainage and intrapleural thrombolytic therapy [Abstract]. American Journal of Respiratory and Critical Care Medicine 2009;179:A4486 [Poster #G115].
Rahman 2011 {published and unpublished data}
    1. Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine 2011;365(6):518‐26. - PubMed
Thommi 2012 {published data only}
    1. Thommi G, Shehan JC, Robison KL, Christensen M, Backemeyer LA, McLeay MT. A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respiratory Medicine 2012;106(5):716‐23. - PubMed
Tuncozgur 2001 {published and unpublished data}
    1. Tuncozgur B, Ustunsoy H, Dikensoy O, Topal M, Sanli M, Elbeyli L. Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial. International Journal of Clinical Practice 2001;55(10):658‐60. - PubMed

References to studies excluded from this review

Anonymous 2016 {published data only}
    1. Anonymous. 21st Congress of the Asian Pacific Society of Respirology; 2016 Nov 12‐15; Bangkok. 2016; Vol. 21:S3.
Anonymous 2019 {published data only}
    1. Anonymous. CHEST 2019 Regional Congress Abstracts. Chest 2019;Conference: CHEST 2019 Regional Congress. Greece. 155(6 Supplement):A327‐88.
Ayed 2013 {published data only}
    1. Ayed A, Shehab D. Role of intrapleural tissue plasminogen in management of complicated pleural effusion. Cardiothoracic Surgery 2013;144(4):108A.
Bachmayer 2011 {published data only}
    1. Bachmayer K. Tissue plasminogen activator and DNase in empyema. New England Journal of Medicine 2011;365(20):1936; author reply 1936‐7. - PubMed
Bashir 2013 {published and unpublished data}
    1. Bashir M, Mousbah H, Gdeedo A. Effectiveness and safety of tissue plasminogen activators (t‐PA) in complicated pleural effusion (CPE), what is the correlation with time it stays in the pleural space?. European Respiratory Journal 2013;42:5040.
Beckert 2019 {published data only}
    1. Beckert L, Brockway B, Simpson G, Southcott AM, Lee YCG, Rahman N, et al. Phase 1 trial of intrapleural LTI‐01; single chain urokinase in complicated parapneumonic effusions or empyema. JCI Insight 2019;4(10):e127470. - PMC - PubMed
Bilaçeroglu 1997 {published data only}
    1. Bilaçeroglu S, Cagirici U, Cakan A, Kumcuoglu Z, Perim K. Management of complicated parapneumonic pleural effusions with image‐guided drainage and intrapleural urokinase or streptokinase: a controlled randomized trial. European Respiratory Journal 10;Suppl 25:325s.
Bouros 2006 {published data only}
    1. Bouros D, Antoniou KM, Light RW. Intrapleural streptokinase for pleural infection. BMJ 2006;332(7534):133‐4. - PMC - PubMed
Cases Viedma 2006 {published data only}
    1. Cases Viedma E, Lorenzo Dus MJ, Gonzalez‐Molina A, Sanchis Aldas JL. A study of loculated tuberculous pleural effusions treated with intrapleural urokinase. Respiratory Medicine 2006;100(11):2037‐42. - PubMed
Chin 1997 {published data only}
    1. Chin NK, Lim T. Controlled trial of intrapleural streptokinase in the treatment of pleural empyema and complicated parapneumonic effusions. Chest 1997;111(2):275‐9. - PubMed
    1. Lim TK, Chin NK. Empirical treatment with fibrinolysis and early surgery reduces the duration of hospitalization in pleural sepsis. European Respiratory Journal 1999;13(3):514‐8. - PubMed
Chung 2003 {published data only}
    1. Chung CL, Chen YC, Chang SC. Effect of repeated thoracenteses on fluid characteristics, cytokines, and fibrinolytic activity in malignant pleural effusion. Chest 2003;123(4):1188‐95. - PubMed
Chung 2008 {published data only}
    1. Chung CL, Chen CH, Yeh CY, Sheu JR, Chang SC. Early effective drainage in the treatment of loculated tuberculous pleurisy. European Respiratory Journal 2008;31(6):1261‐7. - PubMed
CTRI/2018/08/015361 2018 {published data only}
    1. CTRI/2018/08/015361. Empyema of lung treatment. www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2018/08/015361 2018.
Fernandez 2007 {published data only}
    1. Fernández Fernández A, Giachetto Larraz G, Giannini Fernandez G, Garat Gomez MC, Vero Acevedo MA, Pastorini Correa J, et al. Intrapleural streptokinase in the treatment of complicated parapneumonic empyema. Anales de Pediatria (Barcelona, Spain : 2003) 2007;66(6):585‐90. - PubMed
Fester 2012 {published data only}
    1. Fester A. Revisiting intrapleural fibrinolysis in empyema. Thorax 2012;67(4):308.
Froudarakis 2008 {published data only}
    1. Froudarakis ME, Kouliatsis G, Steiropoulos P, Anevlavis S, Pataka A, Popidou M, et al. Recombinant tissue plasminogen activator in the treatment of pleural infections in adults. Respiratory Medicine 2008;102(12):1694‐700. - PubMed
ISRCTN12852177 2008 {published data only}
    1. ISRCTN12852177. A randomised controlled trial to evaluate whether use of intrapleural urokinase aids the drainage of multi‐septated pleural effusion compared to placebo. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN12852177 2008.
Jin 2013 {published data only}
    1. Jin JM, Sun YC. [Evaluation of febrinolytic therapy for treatment of pleural infection]. [Chinese]. Zhonghua Jie He He Hu Xi Za Zhi 2013;36(5):327‐9. - PubMed
Komissarov 2013 {published data only}
    1. Komissarov AA, Florova G, Schaefer C, Rahman NM, Lee YCG, Idell S. Pleural fluids collected during the second multicenter intrapleural sepsis trial (MIST2) demonstrate highly variable fibrinolytic potential prior to the treatment and endogenous fibrinolytic activity depletion during intrapleural fibrinolytic therapy. American Journal of Respiratory and Critical Care Medicine 2013;187:A4313.
Light 2010 {published data only}
    1. Light RW. Management of parapneumonic effusions. Journal of Clinical and Analytical Medicine 2010;1(2):48‐51.
Lim 1999 {published data only}
    1. Lim TK, Chin NK. Empirical treatment with fibrinolysis and early surgery reduces the duration of hospitalization in pleural sepsis. European Respiratory Journal 1999;13(3):514‐8. [PUBMED: 10232418] - PubMed
Maiga 2017 {published data only}
    1. Maiga A, Pinkerman R, Deppen SA, Scruggs J, Mcguire P, Tarpley JL, et al. tPA/DNase for Complicated Parapneumonic Effusions and Empyemas. American Surgeon 2017;83(12):1458‐9. - PMC - PubMed
Maskell 2006 {published data only}
    1. Maskell N, Nunn A, Davies RJ. Intrapleural streptokinase for pleural infection. BMJ 2006;332(7540):552. - PMC - PubMed
Masood 2006 {published data only}
    1. Masood I, Bhargava R, Ahmad Z, Pandey DK, Ahmad S. Role of intrapleural streptokinase in empyema. Journal, Indian Academy of Clinical Medicine : JIACM 2006;7(4):313‐5.
Mathur 2011 {published data only}
    1. Mathur PN. Intrapleural t‐PA plus DNase improved clinical outcomes in patients with pleural infection. Annals of Internal Medicine 2011;155(12):JC6‐9. - PubMed
Muers 1997 {published data only}
    1. Muers MF. Streptokinase for empyema. Lancet 1997;349(9064):1491‐2. - PubMed
NCT00103766 2004 {published data only}
    1. NCT00103766. Randomized comparison of two dose and frequency regimens of alteplase for treatment of empyema and complicated parapneumonic effusion. clinicaltrials.gov/ct2/show/NCT00103766 (First received February 15 2005).
NCT01862458 2013 {published data only}
    1. NCT01862458. Empyema Treated With tPA & DNAse. clinicaltrials.gov/show/NCT01862458 2013.
NCT02973139 2016 {published data only}
    1. NCT02973139. Fibrinolysis Compared to Thoracoscopy for Pleural Infection. clinicaltrials.gov/show/NCT02973139 2016.
NCT03172052 2017 {published data only}
    1. NCT03172052. Evaluating Different Modalities for Pleural Adhesiolysis at Assuit University Hospital. clinicaltrials.gov/show/nct03172052 2017.
Ruiz 2006 {published data only}
    1. Ruiz A, Porcel JM, Madronero AB, Galindo C. Hemothorax following administration of intrapleural alteplase. Respiration 2006;73(5):715. - PubMed
Shah 2006 {published data only}
    1. Shah NN, Bachh AA, Bhargava R, Ahmad Z, Panday DK, Shameem Mohd. Role of intrapleural streptokinase in management of multiloculated thoracic empyemas. JK Practitioner 2006;13(2):91‐4.
Skeete 2004 {published data only}
    1. Skeete DA, Rutherford EJ, Schlidt SA, Abrams JE, Parker LA, Rich PB. Intrapleural tissue plasminogen activator for complicated pleural effusions. Journal of Trauma 2004;57(6):1178‐83. - PubMed
Talib 2003 {published data only}
    1. Talib SH, Verma GR, Arshad M, Tayade BO, Rafeeque A. Utility of intrapleural streptokinase in management of chronic empyemas. Journal of the Association of Physicians of India 2003;51:464‐8. - PubMed
Tsang 2007 {published data only}
    1. Tsang KY, Leung WS, Chan VL, Lin AW, Chu CM. Complicated parapneumonic effusion and empyema thoracis: microbiology and predictors of adverse outcomes. Hong Kong Medical Journal 2007;13(3):178‐86. - PubMed
Wong 2006 {published data only}
    1. Wong K‐S. Is intrapleural streptokinase instillation a routine for parapneumonic empyema?. Acta Paediatrica Taiwanica 2006;47(2):59‐60. - PubMed
Zuckerman 2009 {published data only}
    1. Zuckerman DA, Reed MF, Howington JA, Moulton JS. Efficacy of intrapleural tissue‐type plasminogen activator in the treatment of loculated parapneumonic effusions. Journal of Vascular and Interventional Radiology 2009;20(8):1066‐9. - PubMed

Additional references

Chung 2005
    1. Chung CL, Chen CH, Sheu JR, Chen YC, Chuang SC. Proinflammatory cytokines, transforming growth factor‐beta1, and fibrinolytic enzymes in loculated and free‐flowing pleural exudates. Chest 2005;128(2):690‐7. - PubMed
Davies 2010
    1. Davies HE, Davies RJO, Davies CWH. Management of pleural infection in adults: British Thoracic Society pleural disease guideline 2010. Thorax 2010;65(Suppl 2):ii41‐ii53. - PubMed
Farjah 2007
    1. Farjah F, Symons RG, Krishnadasan B, Wood DE, Flum DR. Management of pleural space infections: a population‐based analysis. Journal of Thoracic and Cardiovascular Surgery 2007;133(2):346‐51. - PubMed
GRADEpro GDT [Computer program]
    1. McMaster University (developed by Evidence Prime). GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), (accessed before 18 September 2019).
Grijalva 2011
    1. Grijalva CG, Zhu Y, Nuorti JP, Griffin MR. Emergence of parapneumonic empyema in the USA. Thorax 2011;66(8):663‐8. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Idell 1991
    1. Idell S, Girard W, Koenig KB, McLarty J, Fair DS. Abnormalities of pathways of fibrin turnover in the human pleural space. American Review of Respiratory Disease 1991;144(1):187‐94. - PubMed
Idell 2005
    1. Idell S. Update on the use of fibrinolysins in pleural disease. Clinical Pulmonary Medicine 2005;12(3):184‐90.
Janda 2012
    1. Janda S, Swiston J. Intrapleural fibrinolytic therapy for treatment of adult parapneumonic effusions and empyemas: a systematic review and meta‐analysis. Chest 2012;142(2):401‐11. - PubMed
LeMense 1995
    1. LeMense PG, Strange C, Sahn SA. Empyema thoracis. Therapeutic management and outcome. Chest 1995;107(6):1532‐7. - PubMed
Light 1985
    1. Light RW. Parapneumonic effusion and empyema. Clinical Chest Medicine 1985;6(1):55‐62. - PubMed
Light 2000
    1. Light RW, Nguyen T, Mulligan ME, Sasse SA. The in vitro efficacy of varidase versus streptokinase or urokinase for liquefying thick purulent exudative material from loculated empyema. Lung 2000;178(1):13‐8. - PubMed
Nie 2014
    1. Nie W, Liu Y, Ye J, Shi L, Shao F, Ying K, Zhang R. Efficacy of intrapleural instillation of fibrinolytics for treating pleural empyema and parapneumonic effusion: a meta‐analysis of randomized control trials.. Clinical Respiratory Journal 2014;8(3):281‐91. - PubMed
Piccolo 2015
    1. Piccolo F, Popowicz N, Wong D, Lee YCG. Intrapleural tissue plasminogen activator and deoxyribonuclease therapy for pleural infection. Journal of Thoracic Diseases 2015;7(6):999‐1008. - PMC - PubMed
Review Manager 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Sahn 1993
    1. Sahn SA. Management of complicated parapneumonic effusions. American Review of Respiratory Disease 1993;148(3):813‐7. - PubMed
Scarcia 2015
    1. Scarcia M, Abaha U, Piergiorgio S, Pagea A, Wallerb D, Schilc P, et al. EACTS expert consensus statement for surgical management of pleural empyema. European Journal of Cardiothoracic Surgery 2015;48(5):642‐53. - PubMed
Shen 2017
    1. Shen KR, Bribiesco A, Crabtree T, Denlinger C, Eby J, Eiken, P, et al. The American Association of Thoracic Surgery consensus guidelines for the management of empyema. Journal of Thoracic and Cardiovascular Surgery 2017;153(6):e129‐e146. - PubMed
Singh 2004
    1. Singh M, Mathew JL, Chandra S, Katariya S, Kumar L. Randomised controlled trial of intrapleural streptokinase in empyema thoracis in children. Acta Paediatrica 2004;93(11):1443‐5. - PubMed
Strange 1999
    1. Strange C, Sahn SA. The definitions and epidemiology of pleural space infection. Seminars in Respiratory Infections 1999;14(1):3‐8. [PUBMED: 10197392] - PubMed
Thommi 2000
    1. Thommi G, Shehan C, Bell A, Coughlin N, McLeay M. Intrapleural instillation of TPA in the management of complicated pleural effusions. Chest 2000;118(Suppl 4):S164.
Thomson 2002
    1. Thomson AH, Hull J, Kumar MR, Wallis C, Balfour Lynn IM. Randomised controlled trial of intrapleural urokinase in the treatment of childhood empyema. Thorax 2002;57(4):343‐7. - PMC - PubMed
Tillett 1951
    1. Tillett WS, Sherry S, Read CT. The use of streptokinase‐streptodornase in the treatment of post‐pneumonic empyema. Journal of Thoracic Surgery 1951;21(3):275‐97. - PubMed
Walker 2003
    1. Walker CA, Shirki MB, Marva MT, Visconti J. Intrapleural alteplase in a patient with complicated pleural effusion. Annals of Pharmacotherapy 2003;37(3):376‐9. - PubMed

References to other published versions of this review

Cameron 1999
    1. Cameron R, Davies H. Intra‐pleural fibrinolytic therapy for parapneumonic effusions and empyema. Cochrane Database of Systematic Reviews 1999, Issue 4. [DOI: 10.1002/14651858.CD002312] - DOI - PubMed
Cameron 2004
    1. Cameron R, Davies HR. Intra‐pleural fibrinolytic therapy versus conservative management in the treatment of parapneumonic effusions and empyema. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD002312.pub2] - DOI - PubMed
Cameron 2008
    1. Cameron R, Davies HR. Intra‐pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema. Cochrane Database of Systematic Reviews 2008;16(2):CD002312. - PubMed

MeSH terms

LinkOut - more resources